GLP-1 users with obesity and kidney disease had lower kidney failure risk in real-world data
A retrospective study at ASN Kidney Week found adults with chronic kidney disease and obesity but no diabetes who took GLP-1 medicines had kidney failure in about 3.3% of cases over five years versus 6.0% of matched non-users, with lower death and heart failure rates too. The lead researcher cautioned that the effect sizes are likely inflated by bias and should be read as a signal, not proof.
Source: Pharmacy Times (27 Oct 2026). Image: Pharmacy Times.